このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

振戦症候群の臨床的および生理学的研究

Background:

Researchers have some data on how the brain controls movement and why some people have tremor. But the causes of tremor are not fully known. Researchers want to study people with tremor to learn about changes in the brain and possible causes of tremor.

Objective:

To better understand how the brain controls movement, learn more about tremor, and train movement disorder specialists.

Eligibility:

People ages 18 and older with a diagnosed tremor syndrome

Healthy volunteers ages 18 and older

Design:

Participants will be screened with:

  • Medical history
  • Physical exam
  • Urine tests
  • Clinical rating scales
  • Health questions
  • They may have electromyography (EMG) or accelerometry. Sensors or electrodes taped to the skin measure movement.

Participation lasts up to 1 year.

Some participants will have a visit to examine their tremor more. They may have rating scales, EMG, and drawing and writing tests.

Participants will be in 1 or more substudies. These will require up to 7 visits. Visits could include the following:

  • EMG with accelerometry
  • Small electrodes taped on the body give small electric shocks that stimulate nerves.
  • MRI: Participants lie on a table that slides into a cylinder that takes pictures of the body while they do simple tasks.
  • Small electrodes on the scalp record brain waves.
  • A cone with detectors on the head measures brain activity while participants do tasks.
  • A wire coil held on the scalp gives an electrical current that affects brain activity.
  • Tests for thinking, memory, smell, hearing, or vision
  • Electrodes on the head give a weak electrical current that affects brain activity.
  • Photographs or videos of movement

Participant data may be shared with other researchers.

調査の概要

状態

完了

条件

詳細な説明

Objectives

The purpose of this protocol is to study the phenotypic spectrum and the pathophysiology of tremor syndromes by performing small behavioral, electrophysiological and neuroimaging sub-studies. The protocol includes techniques with minimal risk (standard clinical evaluation, MRI, EEG, peripheral nerve stimulation, single and paired pulse TMS) and certain sub-studies may involve healthy volunteers. This protocol aims to study neurophysiological and behavioral outcomes in defined groups of patients with tremor syndromes, to inform future hypothesis-driven and confirmatory studies, which will be developed and submitted as separate protocols. For this purpose, we aim to conduct 1) pilot sub-studies, 2) individual patient investigations, 3) technical development studies.

Study population

We intend to enroll up to 300 patients with essential tremor and other isolated action tremor syndromes, as well as 150 healthy volunteers.

Design

This is a non-hypothesis driven study involving standardized phenotyping After patients and healthy volunteers complete a screening visit, patients will undergo a standardized phenotyping visit including clinical rating scales as well as electrophysiological tremorworkup. Patient and healthy controls may then be enrolled in sub-studies, and if a substudy leads to results of interest, a separate protocol will be submitted with a priori hypotheses, specific study design and power analysis adapted from the pilot or exploratory sub-studies performed in the present protocol.

Outcome measures

Outcome measures applied in this protocol involve methods for tremor phenotyping such as clinical rating scales and questionnaires, electrophysiological tremor studies, videotaped exam, as well as digitizing based tasks. During the sub-studies focused on the neurophysiological characterization of tremor syndromes, the following outcome measures will be applied: EMG: we will analyze tremor signals using spectral analyses, coherence analyses, and in combination with accelerometry, EEG, MEG, and TMS to explore tremor-networks. MRI: we will analyze measures such as the amplitude of the BOLD signal (fMRI); tractography between seed and target regions of interest (using DTI); morphometry of brain regions (using VBM); and different neurotransmitter levels in brain regions of interest (using MRS). EEG and MEG: we will quantify measures such as corticomuscular coherence, event- or task-related potentials, synchronization/desynchronization, and coherence between sensors or sources located close to the brain areas of interest. TMS: we will analyze measures such as MEP amplitude and central conduction time, as well as measures of cortical excitability and inhibition paradigms. Behavioral measures: we will quantify measures of voluntary movement involving tremor, reaction times to initiate movements, EMG patterns, movement kinematics (position, velocity, acceleration, curvature), eye movement. Actigraphy: We will quantify continuous recordings of motion sensors involving multiaxial accelerometers and gyroscopes. Furthermore, we may measure autonomic data during the course of experiments (such as blood pressure, skin co ductance, and respiratory rate) which would correlate to the outcome measures.

研究の種類

観察的

入学 (実際)

85

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Maryland
      • Bethesda、Maryland、アメリカ、20892
        • National Institutes of Health Clinical Center

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

サンプリング方法

非確率サンプル

調査対象母集団

Experimental subjects will include healthy volunteer subjects and patients with tremor syndromes including, but not limited to ET, PD-tremor, and dystonic tremor. The diagnosis will be made by a movement disorders neurologist at the NINDS movement disorders clinics. Healthy volunteers will be recruited for the following purposes: (1) to optimize data acquisition and analysis techniques; and (2) to serve as negative controls for clinical, imaging, and biological variables measured in the patient cohorts. Without data obtained from healthy volunteers, there is no way to determine whether subtle findings in tremor (e.g., physiological tremor) are truly abnormal. The inclusion of healthy volunteers therefore allows to correctly threshold and quantify observed abnormalities. Healthy volunteers may also include non-affected family members of patients with tremor

説明

  • INCLUSION CRITERIA FOR TREMOR PATIENTS:

  • Patients diagnosed with a tremor syndrome, including, but not limited to

    • Essential tremor (per definition of the Tremor Research Group)
    • Parkinson disease (per UK Brain Bank criteria)
    • Focal tremor such as isolated head tremor, voice tremor
    • Task-specific tremor such as primary writing tremor
    • Orthostatic tremor
    • Patients with other tremor syndromes such as dystonic tremor, intention tremor, etc.
  • Age 18 or older

  • Able to give informed consent

  • Agree to not drink caffeine or alcohol for 12 hours before phenotyping and selected sub-study visits because both agents can modify brain activity and may confound outcome measures.

INCLUSION CRITERIA FOR HEALTHY VOLUNTEERS:

  • Age 18 or older.
  • Able to give informed consent.
  • Agree to not consume caffeine or alcohol for 12 hours before selected sub-study visits because both agents may modify the activity of the brain during the study.

EXCLUSION CRITERIA FOR TREMOR PATIENTS:

  • Problematic alcohol use, as defined by a score of 8 or higher on the WHO Alcohol Use Disorders Identification Test (AUDIT).
  • History of a brain tumor, a stroke, traumatic brain injury, epilepsy or a history of seizures.
  • History of psychotic disorder, Bipolar Disorder or a current depressive episode.
  • History or clinical evidence of another neurologic disorder than a tremor syndrome as defined above, which may interfere with the ability to comply with protocol requirements or interpret the obtained results.

EXCLUSION CRITERIA FOR HEALTHY VOLUNTEERS:

  • Have abnormal findings of clinical significance on the neurological examination that may affect the scientific integrity of the study
  • Problematic alcohol use, as defined by a score of 8 or higher on the WHO Alcohol Use Disorders Identification Test (AUDIT)
  • History of a brain tumor, a stroke, traumatic brain injury, epilepsy or a history of seizures.
  • History of psychotic disorder, Bipolar Disorder or a current depressive episode.

ADDITIONAL EXCLUSION CRITERIA FOR MOVEMENT DISORDER PATIENTS AND HEALTHY VOLUNTEERS SPECIFICALLY FOR MRI:

We will follow the NMR Center guidelines for MR safety.

Some of the exclusions are:

  • Have non-MRI compatible metal in the body, such as a cardiac pacemaker, brain stimulator, shrapnel, surgical metal, clips in the brain or on blood vessels, cochlear implants, artificial heart valves or ferromagnetic fragments in the eye or oral cavity as these make having an MRI unsafe.
  • Unable to lie flat on the back for the expected length of the experiment.
  • Have uncontrolled movements of the head.
  • Have an abnormality on the brain imaging or neurologic examination not related to the diagnosis.
  • Uncomfortable being in a small space for the expected length of the experiment.
  • Non-removable body piercing or tattoo posing MRI risk
  • Pregnancy.

ADDITIONAL EXCLUSION CRITERIA FOR TREMOR PATIENTS AND HEALTHY VOLUNTEERS FOR TMS AND MRI:

  • Ferromagnetic metal in the cranial cavity or eye, e.g. aneurysm clip or ocular foreign body.
  • Implanted electronic device including deep brain stimulation systems.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:CASE_CONTROL
  • 時間の展望:PROSPECTIVE

コホートと介入

グループ/コホート
Healthy Volunteers

adult healthy volunteers

tremor patients

adult patients with tremor

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
methods for tremor phenotyping
時間枠:throughout protocol

clinical rating scales and questionnaires, electrophysiological tremor studies, videotaped exam, as well as digitizing based tasks. EMG, EEG, MEG, TMS, MRI. Behavioral measures such as reaction times to initiate movements, EMG patterns, movement kinematics, eye movement.

throughout protocol

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Debra J Ehrlich, M.D.、National Institute of Neurological Disorders and Stroke (NINDS)

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2017年5月5日

一次修了 (実際)

2022年3月23日

研究の完了 (実際)

2022年3月23日

試験登録日

最初に提出

2017年1月18日

QC基準を満たした最初の提出物

2017年1月20日

最初の投稿 (推定)

2017年1月23日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月18日

QC基準を満たした最後の更新が送信されました

2026年9月17日

最終確認日

2026年9月16日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 170035
  • 17-N-0035

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

We will share all collected deidentified IPD at the request of others after publication. Data will not be sent until the applicable approvals and data sharing agreement has been obtained.

IPD 共有時間枠

Starting 6 months after publication.

IPD 共有アクセス基準

Requests will be considered on a case-by-case basis and we will try to uphold the NIH data-sharing directive. At the same time we may need IRB approval and/or data sharing agreements to be in place before we send data to others.

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。